Faculty Collaboration Database

Dissection of PIK3CA Aberration for Cervical Adenocarcinoma Outcomes. Cancers (Basel) 2021 Jun 28;13(13)

Date

07/03/2021

Pubmed ID

34203201

Pubmed Central ID

PMC8269188

DOI

10.3390/cancers13133218

Scopus ID

2-s2.0-85108696152 (requires institutional sign-in at Scopus site)   3 Citations

Abstract

Personalized treatment of genetically stratified subgroups has the potential to improve outcomes in many malignant tumors. This study distills clinically meaningful prognostic/predictive genomic marker for cervical adenocarcinoma using signature genomic aberrations and single-point nonsynonymous mutation-specific droplet digital PCR (ddPCR). Mutations in PIK3CA E542K, E545K, or H1047R were detected in 41.7% of tumors. PIK3CA mutation detected in the patient's circulating DNA collected before treatment or during follow-up was significantly associated with decreased progression-free survival or overall survival. PIK3CA mutation in the circulating DNA during follow-up after treatment predicted recurrence with 100% sensitivity and 64.29% specificity. It is the first indication of the predictive power of PIK3CA mutations in cervical adenocarcinoma. The work contributes to the development of liquid biopsies for follow up surveillance and a possibility of tailoring management of this particular women's cancer.

Author List

Chung TKH, Doran G, Cheung TH, Yim SF, Yu MY, Worley MJ Jr, Elias KM, Thorner AR, Pedamallu CS, Ojesina AI, Lau KM, Ducar MD, Wong RRY, Wang VW, Nag A, Wollison BM, Dalgarno A, Lee JHS, Yeung SY, Wong L, Horowitz NS, Davis MR, Leung SA, Mu Y, Mok SC, Chan PKS, Lawrence MS, Crum CP, Chiu RWK, Berkowitz RS, Wong YF

Author

Akinyemi Ojesina MD, PhD Assistant Professor in the Obstetrics and Gynecology department at Medical College of Wisconsin